REVIVA PHARMACEUTICALS HOLDINGS, INC.

Analysis for Ticker: RVPH

Reviva Pharmaceuticals Holdings Inc operates as a clinical stage biopharmaceutical company specialized in developing therapies for brain disorders and heart conditions but the actual business is a machine designed to transfer wealth from public investors to a specific ecosystem of insiders. While the company claims to be creating the next generation of medicines, it has zero products to sell and zero revenue while carrying an accumulated deficit of 184,1$ million. The math is a disaster because the business is a black hole that needs 90$ million to survive clinical trials but only has a tiny fraction of that amount in its bank account. To a child this looks like one boy who keeps asking for lunch money but instead of buying food he uses it to pay his friends to help him ask for even more money. The financial decay was visible by 2023 when the company lost 39,2$ million yet chief executive officer Laxminarayan Bhat took home 2,76$ million in total compensation. In 2024 the losses continued with another 29,9$ million and an operating cash burn of 24,6$ million but the executives continued to extract value. Bhat received another 607.500$ while the board retroactively increased the base salary of his wife to 340.000$ and chief financial officer Narayan Prabhu to 330.000$. The chief executive officer even maintained family control through an Indian subsidiary.